SNP | Model | Controls | Patients | OR (95% CI) | P | Pc |
---|---|---|---|---|---|---|
-1131 T > C |  |  |  |  |  |  |
 | Codominant |  |  |  |  |  |
 | TT | 128 (95.5%) | 97 (65.1%) | 1.00 |  |  |
 | TC | 2 (1.5%) | 20 (13.4%) | 11.16 (2.46-50.69) | 0.002 | 0.006 * |
 | CC | 4 (3%) | 32 (21.5%) | 14.20 (4.50-44.77) | <0.0001 | <0.0001 * |
 | Dominant |  |  |  |  |  |
 | TT | 128 (95.5%) | 97 (65.1%) | 1.00 |  |  |
 | TC/CC | 6 (4.5%) | 52 (34.9%) | 13.20 (5.14-33.91) | <0.0001 | <0.0001 * |
 | Recessive |  |  |  |  |  |
 | TT/TC | 130 (97%) | 117 (78.5%) | 1.00 |  |  |
 | CC | 4 (3%) | 32 (21.5%) | 12.35 (3.91-39.05) | <0.0001 | <0.0001 * |
56C > G |  |  |  |  |  |  |
 | Codominant |  |  |  |  |  |
 | CC | 117 (87.3%) | 106 (71.1%) | 1.00 |  |  |
 | CG | 15 (11.2%) | 21 (14.1%) | 1.54 (0.72-3.29) | 0.269 | NS |
 | GG | 2 (1.5%) | 22 (14.8%) | 13.75 (3.01-62.75) | 0.001 | 0.003 * |
 | Dominant |  |  |  |  |  |
 | CC | 117 (87.3%) | 106 (71.1%) | 1.00 |  |  |
 | CG/GG | 17 (12.7%) | 43 (28.9%) | 2.90 (1.49-5.63) | 0.002 | 0.006 * |
 | Recessive |  |  |  |  |  |
 | CC/CG | 132 (98.5%) | 127 (85.2%) | 1.00 |  |  |
 | GG | 2 (1.5%) | 22 (14.8%) | 12.77 (2.82-57.73) | 0.001 | 0.003 * |
c.553G > T |  |  |  |  |  |  |
 | Codominant |  |  |  |  |  |
 | GG | 130 (97%) | 132 (88.6%) | 1.00 |  |  |
 | GT | 3 (2.2%) | 15 (10.1%) | 4.72 (1.28-17.35) | 0.020 | NS |
 | TT | 1 (0.8%) | 2 (1.3%) | 1.64 (0.14-19.78) | 0.695 | NS |
 | Dominant |  |  |  |  |  |
 | GG | 130 (97%) | 132 (88.6%) | 1.00 |  |  |
 | GT/TT | 4 (3%) | 17 (11.4%) | 3.92 (1.23-12.43) | 0.02 | NS |
 | Recessive |  |  |  |  |  |
 | GG/GT | 133 (99.2%) | 147 (98.7%) | 1.00 |  |  |
 | TT | 1 (0.8%) | 2 (1.3%) | 1.47 (0.12-17.70) | 0.763 | NS |